EE200000278A - Ühendid Alzheimeri tõve ante mortem diagnoosiks ja in vivo kuvamiseks ning amüloidi ladestumise ärahoidmiseks - Google Patents

Ühendid Alzheimeri tõve ante mortem diagnoosiks ja in vivo kuvamiseks ning amüloidi ladestumise ärahoidmiseks

Info

Publication number
EE200000278A
EE200000278A EEP200000278A EEP200000278A EE200000278A EE 200000278 A EE200000278 A EE 200000278A EE P200000278 A EEP200000278 A EE P200000278A EE P200000278 A EEP200000278 A EE P200000278A EE 200000278 A EE200000278 A EE 200000278A
Authority
EE
Estonia
Prior art keywords
alzheimer
disease
prevention
compounds
vivo imaging
Prior art date
Application number
EEP200000278A
Other languages
English (en)
Estonian (et)
Inventor
E. Klunk William
W. Pettegrew Jay
A. Mathis Chester Jr.
Original Assignee
University Of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Pittsburgh filed Critical University Of Pittsburgh
Publication of EE200000278A publication Critical patent/EE200000278A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/64—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/10—Hydrazines
    • C07C243/22—Hydrazines having nitrogen atoms of hydrazine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C07C245/08—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C07C245/10—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200000278A 1997-11-06 1998-11-06 Ühendid Alzheimeri tõve ante mortem diagnoosiks ja in vivo kuvamiseks ning amüloidi ladestumise ärahoidmiseks EE200000278A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/968,902 US6417178B1 (en) 1994-07-19 1997-11-06 Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
PCT/US1998/023598 WO1999024394A2 (en) 1997-11-06 1998-11-06 Compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition

Publications (1)

Publication Number Publication Date
EE200000278A true EE200000278A (et) 2001-08-15

Family

ID=25514917

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000278A EE200000278A (et) 1997-11-06 1998-11-06 Ühendid Alzheimeri tõve ante mortem diagnoosiks ja in vivo kuvamiseks ning amüloidi ladestumise ärahoidmiseks

Country Status (18)

Country Link
US (1) US6417178B1 (xx)
EP (1) EP1028941A2 (xx)
JP (1) JP2001522829A (xx)
KR (1) KR20010031872A (xx)
CN (1) CN1285818A (xx)
AU (1) AU1383399A (xx)
BR (1) BR9812776A (xx)
CA (1) CA2309626A1 (xx)
EE (1) EE200000278A (xx)
HU (1) HUP0100159A3 (xx)
ID (1) ID25797A (xx)
IL (1) IL135986A0 (xx)
NO (1) NO20002380L (xx)
OA (1) OA11377A (xx)
PL (1) PL348226A1 (xx)
SK (1) SK6732000A3 (xx)
TR (1) TR200001264T2 (xx)
WO (1) WO1999024394A2 (xx)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2001070667A1 (fr) * 2000-03-22 2001-09-27 Bf Research Institute, Inc. Sonde de diagnostic par image, a base d'azobenzene substitue ou d'un analogue de celui-ci, pour les maladies imputables a l'accumulation d'amyloide et composition pour le diagnostic par image le contenant
US7107092B2 (en) 2000-08-21 2006-09-12 The General Hospital Corporation Methods for diagnosing a neurodegenerative condition
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
EP1334091B1 (en) 2000-08-24 2012-09-19 University of Pittsburgh - Of the Commonwealth System of Higher Education Thioflavin derivatives and their use in diagnosis and therapy of alzheimer's disease
US6589504B1 (en) 2000-09-22 2003-07-08 Pharmacia & Upjohn Company Compounds and methods for diagnosing and treating amyloid-related conditions
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
AU2002258915B2 (en) 2001-04-23 2007-11-15 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
NZ545889A (en) * 2001-04-27 2006-06-30 Brigham & Womens Hospital Ocular diagnosis of Alzheimer's disease
US20050227941A1 (en) * 2001-12-17 2005-10-13 Karen Duff Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20050043523A1 (en) * 2003-08-22 2005-02-24 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
EP1631561B1 (en) 2003-05-07 2010-08-18 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
EP1641806B1 (en) * 2003-05-29 2009-07-29 Jay W. Pettegrew Glycerophosphocholine and its derivatives for medical imaging of neuropsychiatric disorders
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US8236282B2 (en) * 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
GB0405193D0 (en) * 2004-03-08 2004-04-21 Medical Res Council Compounds
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
EP1838854B1 (en) * 2004-12-15 2012-10-31 Janssen Alzheimer Immunotherapy Antibodies that recognize Beta Amyloid Peptide
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
EP1907066A4 (en) 2005-07-22 2009-10-21 Tomotherapy Inc SYSTEM AND METHOD FOR THE ADMINISTRATION OF RADIATION THERAPY IN A POTENTIAL INTEREST
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
CA2616272A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of detecting a breathing phase of a patient receiving radiation therapy
JP2009502255A (ja) 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 治療プランのデリバリにおける品質保証基準を評価するための方法およびシステム
EP1906827A4 (en) 2005-07-22 2009-10-21 Tomotherapy Inc SYSTEM AND METHOD FOR EVALUATING THE DOSE USED BY A RADIATION THERAPY SYSTEM
KR20080044250A (ko) 2005-07-23 2008-05-20 토모테라피 인코포레이티드 갠트리 및 진료대의 조합된 움직임을 이용하는 방사선치료의 영상화 및 시행
WO2007047815A2 (en) * 2005-10-18 2007-04-26 The Brigham And Women's Hospital, Inc. Diagnosis of transmissible spongiform encephalopathy
WO2007120755A2 (en) 2006-04-11 2007-10-25 Neuroptix Corporation Ocular imaging
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US7700616B2 (en) * 2006-05-08 2010-04-20 Molecular Neuroimaging, Llc. Compounds and amyloid probes thereof for therapeutic and imaging uses
KR100836753B1 (ko) * 2006-09-08 2008-06-10 한국과학기술연구원 베타 아밀로이드 피브릴 형성 억제 화합물, 이의 제조 방법 및 이를 포함하는 약학 조성물
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CA2688811A1 (en) * 2007-05-21 2008-11-27 Neuroptix Corporation Ophthalmic formulations of amyloid-beta contrast agents and methods of use thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AU2008331439B9 (en) * 2007-12-07 2014-04-10 Prana Biotechnology Ltd Compounds for therapy and diagnosis
US20090162280A1 (en) * 2007-12-20 2009-06-25 General Electric Company Detecting soluble a-beta
EP2247558B2 (en) 2008-02-14 2024-07-03 Eli Lilly and Company Novel imaging agents for detecting neurological dysfunction
WO2009146388A1 (en) 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Voxel-based methods for assessing subjects using positron emission tomography
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CU23844B1 (es) 2009-04-17 2012-10-15 Ct De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
WO2011092796A1 (ja) * 2010-01-28 2011-08-04 パナソニック株式会社 アミロイドβ測定方法
EP2368558A1 (en) 2010-03-23 2011-09-28 Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates
EP2420179B1 (en) 2010-08-16 2020-10-07 Cognoptix, Inc. System and method for detecting amyloid proteins
AU2013323198B2 (en) * 2012-09-28 2018-03-29 Srinivasa R. Cheruku Dihydro-6-azaphenalene derivatives for the treatment of CNS, oncological diseases and related disorders
WO2014133849A2 (en) 2013-02-26 2014-09-04 Accuray Incorporated Electromagnetically actuated multi-leaf collimator
AR098232A1 (es) 2013-10-31 2016-05-18 Cognoptix Inc Métodos de preparación de una formulación oftálmica y usos de la misma
EP3852774A4 (en) * 2018-06-29 2022-03-23 Tets, Viktor, Veniaminovich METHODS OF DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472965A (en) * 1949-06-14 Metallized tetrakisazo dyes
US394841A (en) * 1888-12-18 Carl duisberg
US476336A (en) * 1892-06-07 Fabriken
US493413A (en) * 1893-03-14 Bruno richard seifert
US1314926A (en) * 1919-09-02 Chester e
US401024A (en) * 1889-04-09 Benfabriken
US410057A (en) * 1889-08-27 Liams
US464775A (en) * 1891-12-08 Ors to tfie farbenfabrikek
US718028A (en) * 1900-11-06 1903-01-06 Basf Ag Mixed disazo dye and process of making same.
US888522A (en) * 1908-02-01 1908-05-26 Farbenfab Vorm Bayer F & Co Red tetrazo dye.
US964920A (en) * 1910-04-13 1910-07-19 Corp Chem Fab Griesheim Elektron Disazo dye.
US982509A (en) * 1910-07-15 1911-01-24 Griesheim Elektron Chem Fab Disazo dyestuff.
US995161A (en) * 1910-12-13 1911-06-13 Griesheim Elektron Chem Fab Disazo dyes for wool.
US1784343A (en) * 1922-08-17 1930-12-09 Gen Aniline Works Inc Lew azo dyestuffs
US1660625A (en) * 1926-03-24 1928-02-28 Grasselli Dyestuff Corp Mordant disazo dyestuffs
DE454177C (de) 1926-03-25 1927-12-30 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von beizenziehenden Azofarbstoffen
US1757500A (en) * 1926-12-10 1930-05-06 British Dyestuffs Corp Ltd Relating to manufacture of new secondary disazo dyes from 1:8-aminonaphthol sulphonic acid
FR743076A (xx) * 1931-09-28 1933-03-23
US2012779A (en) * 1933-03-31 1935-08-27 Chem Ind Basel Chromiferous azo-dyestuff and process of making same
US2314023A (en) * 1939-08-08 1943-03-16 Chem Ind Basel Substantive azo dyestuffs and process of making same
US2367053A (en) * 1941-09-06 1945-01-09 Du Pont Disazo dyestuffs
US2803625A (en) * 1951-11-15 1957-08-20 Bayer Ag Chromium complex disazo dyestuffs
US2773864A (en) * 1952-04-19 1956-12-11 Gen Aniline & Film Corp Coupling assistants for polyazo dyes
US2912428A (en) 1956-03-07 1959-11-10 Ciba Ltd Process for the manufacture of azo pigments
US2954371A (en) * 1958-02-12 1960-09-27 Ciba Ltd Water insoluble disazo-dyestuffs
NL250565A (xx) * 1959-04-16
GB1028567A (en) * 1962-08-14 1966-05-04 Sumitomo Chemical Co Improvements in or relating to disazo dyestuffs
NL130680C (xx) * 1965-04-29
US3485814A (en) * 1965-08-12 1969-12-23 Du Pont Disazo sulfonic acid dyes
FR2036652A5 (en) 1969-03-06 1970-12-24 Ciba Geigy Naphthoxazole optical blueing agents
CH553807A (de) 1970-12-23 1974-09-13 Sandoz Ag Verfahren zur herstellung von dibenzthiophendioxidderivaten.
JPS547814B2 (xx) 1971-09-16 1979-04-10
DE2251703A1 (de) * 1972-10-21 1974-05-02 Hoechst Ag Verfahren zum faerben von synthetischen fasermaterialien aus organischen loesemitteln
DE2256171C3 (de) 1972-11-16 1979-07-26 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von Disazopigmenten
JPS5516573B2 (xx) 1972-11-16 1980-05-02
US4006131A (en) * 1973-01-04 1977-02-01 Sandoz Ltd. Anionic disazo dyes having a 2,2'-dihalodiphenyl tetrazo component radical
JPS5817158A (ja) 1981-07-23 1983-02-01 Dainippon Ink & Chem Inc 紫外線を遮断する樹脂組成物
US4933156A (en) * 1987-04-08 1990-06-12 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
DE3725082A1 (de) * 1987-07-29 1989-02-09 Bayer Ag Disazofarbstoffe
US6168776B1 (en) * 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
EP0719837B1 (de) * 1994-12-12 2000-07-26 Ciba SC Holding AG Azofarbstoffe, Verfahren zu deren Herstellung und deren Verwendung
AU712552B2 (en) 1995-05-01 1999-11-11 University Of Pittsburgh Azo compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition

Also Published As

Publication number Publication date
KR20010031872A (ko) 2001-04-16
SK6732000A3 (en) 2002-05-09
EP1028941A2 (en) 2000-08-23
OA11377A (en) 2004-01-28
AU1383399A (en) 1999-05-31
BR9812776A (pt) 2003-06-10
HUP0100159A3 (en) 2002-09-30
NO20002380L (no) 2000-07-04
ID25797A (id) 2000-11-02
WO1999024394A2 (en) 1999-05-20
JP2001522829A (ja) 2001-11-20
NO20002380D0 (no) 2000-05-05
PL348226A1 (en) 2002-05-06
WO1999024394A9 (en) 2001-05-31
CA2309626A1 (en) 1999-05-20
WO1999024394A3 (en) 1999-08-19
HUP0100159A2 (hu) 2001-05-28
IL135986A0 (en) 2001-05-20
TR200001264T2 (tr) 2001-08-21
US6417178B1 (en) 2002-07-09
CN1285818A (zh) 2001-02-28

Similar Documents

Publication Publication Date Title
EE200000278A (et) Ühendid Alzheimeri tõve ante mortem diagnoosiks ja in vivo kuvamiseks ning amüloidi ladestumise ärahoidmiseks
EE9900503A (et) Krüsamiin G alküül-, alkenüül- ja alkünüülderivaadid Alzheimeri tõve ante mortem diagnoosiks ning amüloidi ladestumise ärahoidmiseks ja in vivo kuvamiseks
AU8670201A (en) Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
DK0806968T3 (da) Diagnostiske billeddannelseskontrastmidler med foröget blodretention
EP0906573A4 (en) METHODS FOR DIAGNOSING THE CLINICAL SUBTYPES OF MORBUS CROHN.
IL105216A0 (en) Method and kit for the diagnosis of alzheimer's disease
AP2001002102A0 (en) Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas
NO953262D0 (no) Bedring av Dupuytrens sykdom
HUP9900426A3 (en) Amyloid binding azoderivatives, preparation thereof and use of these compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
NO20002517D0 (no) Magnetisk resonansavbildningsmidler for deteksjon av fysiologiske midler
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
DE69604228T2 (de) Pupillen Messanordnung und Alzheimer Krankheits Diagnosesystem
HUP0003684A3 (en) Diagnostic test for alzheimer's disease
DE69825888D1 (de) Diagnostisches verfahren der alzheimer-erkrankung
AU5153398A (en) Diagnostic method for the detection of alzheimer's disease in living patients
IL117695A0 (en) Pharmaceutical agents for the treatment of alzheimer's disease
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
FR2725023B1 (fr) Diagnostic direct d'haptenes
GB9825948D0 (en) Diagnosis of spongiform disease
HUP0103149A3 (en) Pharmaceutical composition for treatment of alzheimer's disease
FR2766927B1 (fr) Methodes et kits pour le diagnostic de la maladie d'alzheimer
GB2340939B (en) Improvements in or relating to diagnosis of disease
ITMI942036A0 (it) Procedimento per determinare la stabilita' degli asfalteni in olio vivo